Bennett J M, Weich D J, Schoeman H S
Department of Cardiology, University of Pretoria.
S Afr Med J. 1988 Dec 17;74(12):619-21.
A 20-week double-blind randomised study of 50 black hypertensive patients was designed to compare the efficacy and safety of indoramin (Baratol; Wyeth/Ayerst) and propranolol in patients who did not respond to diuretic therapy alone. Indoramin (initial dose 50 mg/d) or propranolol (initial dose 80 mg/d) was added to the regimen of patients whose supine diastolic blood pressure (SDBP) remained elevated at 100- 200 mmHg after 2 weeks' treatment with a combination diuretic tablet (hydrochlorothiazide 50 mg plus amiloride HCl 5 mg). Supine systolic blood pressure (SSBP) and SDBP of all patients was successfully controlled (SDBP lowered to less than 95 mmHg) by daily doses that did not exceed 100 mg of indoramin or 160 mg of propranolol; over 90% of patients in each group achieved control with lower doses, i.e. 50-75 mg of indoramin or 80-120 mg of propranolol. Although heart rate decreased from baseline values by approximately 9/min with both agents, the decreases were not significantly different between the treatment groups, and neither agent caused orthostatic hypotension. There were no statistically significant differences between the groups in the types or frequency of side-effects. Indoramin is well tolerated and is as effective as propranolol in black patients with essential hypertension who are not controlled by a thiazide diuretic alone.
一项针对50名黑人高血压患者的为期20周的双盲随机研究，旨在比较吲哚拉明（Baratol；惠氏/艾尔斯特公司）和普萘洛尔在仅接受利尿剂治疗无效的患者中的疗效和安全性。对于在联合使用利尿剂片剂（氢氯噻嗪50毫克加盐酸阿米洛利5毫克）治疗2周后仰卧位舒张压（SDBP）仍维持在100 - 200毫米汞柱的患者，在其治疗方案中添加吲哚拉明（初始剂量50毫克/天）或普萘洛尔（初始剂量80毫克/天）。所有患者的仰卧位收缩压（SSBP）和SDBP通过每日不超过100毫克吲哚拉明或160毫克普萘洛尔的剂量成功得到控制（SDBP降至95毫米汞柱以下）；每组超过90%的患者通过更低剂量即50 - 75毫克吲哚拉明或80 - 120毫克普萘洛尔实现了血压控制。尽管两种药物治疗后心率均较基线值下降约9次/分钟，但各治疗组之间的下降幅度无显著差异，且两种药物均未引起体位性低血压。两组在副作用类型或频率方面无统计学显著差异。在仅用噻嗪类利尿剂无法控制血压的黑人原发性高血压患者中，吲哚拉明耐受性良好且与普萘洛尔疗效相当。
